Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Treatment for Treatment-Experienced, HIV-Infected People

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection~* Triple-class drug experience or resistance. More information on this criterion can be found in the protocol.~* Currently on a failing PI-containing regimen that includes 2 other ARVs with no regimen change for 8 weeks prior to study screening~* HIV viral load of 1000 copies/ml or more~* Hepatitis B surface antigen negative within 90 days of study entry~* Able to obtain NRTIs and ritonavir and have required ARVs at time of starting study intervention~* Willing to use acceptable forms of contraception~* Parent or legal guardian willing to provide consent, if applicable~* CD4 count result from a specimen drawn within 120 days prior to study entry~* If any previous HIV-1 viral co-receptor tropism result is available, then most recent specimen date and the tropism result of that specimen AND specimen date and tropism result of any test with either X4 or D/M result, if different from the first specimen, must be available~Inclusion Criteria continued:~* Receipt of successful phenotype/genotype resistance results within 105 days prior to study treatment intervention assignment~* Study team identification of a study regimen and at least 2 NRTIs for participant to take~* Certain abnormal laboratory values. More information on this criterion can be found in the protocol.~Exclusion Criteria:~* Chronic, active hepatitis B virus infection (hepatitis B surface antigen positive or HBV DNA positive)~* Taking certain medications. More information on this criterion can be found in the protocol.~* Known allergy/sensitivity to components of two or more of the study-provided drugs or their formulations. For maraviroc, this includes hypersensitivity or history of allergy to soy lecithin or peanuts.~* Active drug or alcohol use that, in the opinion of the investigator, may interfere with the study~* Pregnancy or breastfeeding~* Use of any immunomodulator (interferons, interleukins, systemic corticosteroids, or cyclosporine), vaccine, or investigational therapy within 30 days prior to study treatment allocation/assignment~* Require certain medications prohibited with study treatment~* Serious illness requiring systemic treatment or hospitalization. Participants who complete therapy or are clinically stable on therapy for at least 14 days prior to study treatment allocation are not excluded.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Regimen with higher predicted activity assigned by the study plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
- B (Type: EXPERIMENTAL): Regimen with higher predicted activity assigned by the study without NRTIs for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
- C (Type: OTHER): Regimen with lower predicted activity assigned plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete